once again, CWNM, is bringing sexy back

OTPicks Newsletter

On-Time-Picks ^OTPicks.com CROWN MARKETING (CWNM) ) Dear Members, We are recently coming out of our YFRM alert at around $.06 – $.08 cents it is currently trading in the $.15 cent range posting 170+% in gains for our members.

We are now, once again, turning our focus back on CWNM again as we have been hearing some things! Crown Marketing is a company that we have featured twice previously. The first time we alerted our members on CWNM it ended up over 30% on the day giving our members a great opprotunity to cash in on gains. Just last week we alerted our members when we heard rumblings of huge news coming out on CWNM again! Members who took our word saw CWNM trade at great levels running from .10 cents all the way up to .146 cents! The Time Is Now Well here at OTPicks.com we are hearing a rumor that more noise will be coming out of Crown Marketing`s camp. We suggest that you put this one on your radar tomorrow as CWNM has historically shown the ability to give our members the opprotunity to lock in some nice gains whenever news has been announced.

If you missed our first alert on this stock here is some brief information on the company:

THE PRODUCT Crown Marketing has developed and patented a novel drug delivery device that had broad applications and benefits to the oral Rx medication and supplement market.

The spectrum and reliability of pharmacokinetic profiles achievable with this technology appears to be superior to currently marketed formulations.

THE INDUSTRY AND LIFE CYCLE MANAGEMENT In addition to the benefit of a more effective drug delivery system, and by extension allowing for decreased dosages and the reduction of possible elimination of side effects, the cash cow for this company lies in its ability to potentially extend patent protection for the horde of multi-billion dollar blockbuster drugs facing the dreaded patent cliff.

2012 may be the year that the patent cliff reaches its height, with $33 billion of sales at risk, but the impact of loss of exclusivity will continue to reverberate across the decade, with more then $290 billion of prescription drugs sales due to be exposed to generic competition between now and 2018.

This is the worst year, but it will also be bad in succeeding years, said Jonathan de Pass, founder and CEO of EvaluatePharma, the consulting firm that compiled the data. The somewhat depressing conclusions of the report, World Preview 2018, were discussed at BIO 2012 on Tuesday, as the largest partnering-fest of the year got into its swing.

In the past 10 years, a huge amount of money has been thrown at acquisitions and the restructuring of research and development (R&D), in an attempt to replace the revenues that are under threat from patent expiries. Over the same time, EvaluatePharma estimated that $1.1 trillion has been invested in R&D in a bid to revitalize pipelines.

In 2010, the pharmaceutical industry had sales of $860 billion worldwide, up 3% from 2009. Just 133 blockbuster drugs accounted for $295 billion of those salesabout 34% of the market. Of those blockbusters, 13 are set to lose patent protection through 2017 EXAMPLES OF CROWNS TECHNOLOGY POTENTIAL Crowns technology will allow drug companies to modify the delivery, pharmacokinetics and dosage that, in addition to significantly reducing or eliminating side effects, it would be patentable. New patents can run for 20 years.

Example: Lipitor Cholesterol fighter Lipitor held the title best selling drug for a few years, and had been a major source of income for the worlds biggest drug company, Pfizer.

Lipitor (atorvastatin) was released in 1998, and by 2006 it had reached worldwide peak sales of $12.9 billion, accounting for 27% of the companys revenue.

In 2010, with $10.8 billion in sales, Lipitor still accounted for 15.8% of Pfizers total revenue. Unfortunately, Lipitor lost its patent protection and cut Pfizers total net income by 50%. Pfizers CEO Ian Read stated on January 31, 2012, in USA TODAY: Patent losses cost the company $5 billion dollars.

CONCLUSSION If Crown can rejuvenate ageing pharmaceutical assets to counteract generic threats and preserve market share and income streams, it could become one of the more successful specialty pharmaceutical companies in memory.

Pharmaceutical companies desperately need to protect their revenue streams especially towards the end of their patent life, as this is when their products are most profitable. For that reason, upfront and milestone payments should be significant and commensurate to the perceived value brought to the project by adopting CDDT technology.

In addition to milestone payments, royalties would continue for the life of the newly patented product. For drug delivery companies, royalty rates are generally accepted to be in the 7% to 12% range depending on the time and expense of adopting the extended release mechanism. Crowns strong patent estate and low development costs for new formulations appears to provide for the least expensive and expedient method for preserving patents and revenue streams.

Your OTPicks.com Editor.

MUST READ DISCLAIMER BELOW ON-TIME-PICKS [1][2] Email: info@OTPicks.com Website: http://www.OTPicks.com MUST READ ENTIRE DISCLAIMER The disclaimer is to be read and fully understood before using our site, or joining our newsletter email list.

Never invest into a stock discussed on this web site or the [3] www.otpicks.com newsletter unless you can afford to lose your entire investment.Please consult with a certified financial advisor before making any investment decisions. [4] www.otpicks.com and any affiliates and information providers make no implied or express warranties on the information provided. Please verify quotes with your investment manager before making investment decisions. This is not to be construed as a solicitation to buy or sell securities. As with any stock, the featured companies in the profiled on the [5] www.otpicks.com web site and/or newsletter involve a high degree of risk and volatility, and all investors should know that they may lose a portion or all of their investment if they decide to purchase any stock.

www.otpicks.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies and does not guarantee the topicality, correctness, completeness and quality of information and statements presented on www.otpicks.com or in email alerts released by [6] www.otpicks.com All information on featured companies is provided by third parties or is available from public sources, regardless all information should not be deemed a primary or reliable source for due diligence.

Any claims or statements should be deemed apocryphal. 100% Accuracy statement is based on any alert rising at least 5% anytime after our initial alert. [7] www.otpicks.com corporate officers, nor any of its affiliates are not registered investment advisors or broker dealers and do not recommend to buy, hold, or sell any securities. [8] www.otpicks.com simply provides a starting point for site members and viewers for which to compare their own thoughts to www.otpicks.com corporate officers. The onus is on site members and viewers to complete their own due diligence. www.otpicks.com members and viewers should always make their own financial decisions. The accuracy and completeness of the information within any report, newsletter or on the web site is only as reliable as the information that is provided to www.otpicks.com in drafting the report.

www.otpicks.com does not verify the information, and makes no warranty that the information is accurate.

Visitors to www.otpicks.com web site and readers of the www.otpicks.com newsletters are cautioned that small and micro-cap stocks are high-risk investments and that SOME or ALL investment dollars CAN be LOST. We suggest you consult a professional investment advisor before purchasing any stock. All opinions expressed at the www.otpicks.com web site are the opinions of [9] www.otpicks.com . All information concerning the companies is received directly from the companies profiled and/or outside interviews conducted by [10] www.otpicks.com . [11] www.otpicks.com . recommends you use the information found here as an initial starting point for conducting your own research and conduct your own due diligence (DD) on the featured companies in order to determine your own personal opinion of the company BEFORE investing in these or any other companies. www.otpicks.com assumes all information to be truthful and reliable; however, we cannot and do not warrant or guarantee the accuracy of this information. All statements contained herein are deemed to be factual as of the date of this report and as such are subject to change without notice.

www.otpicks.com is NOT an Investment Advisor, Financial Planning Service or a Stock Brokerage Firm and in accordance with such www.otpicks.com is not offering Any Type Of Advice or promoting any investment strategies. [12] www.otpicks.com is not offering securities for sale or solicitation of any offer to buy or sell securities. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. On occasion [13] www.otpicks.com receives compensation from a third party REGARDLESS OF HIS/HER relation to the Companies being profiled in its Newsletters sent to our subscribers. In such a case www.otpicks.com directly mentions at the bottom of this disclaimer along with the exact form and amount of compensation. [14] www.otpicks.com , its affiliates, associates, relatives and anyone associated with [15] www.otpicks.com in any manner reserves the right to either BUY or SELL shares in the profiled companys stock, either BEFORE the date of the profile, DURING the date of the profile or at ANY time after the date of the profile. Do your own research and due diligence (DD) before investing in any company. www.otpicks.com merely is providing information and is in no way nor manner suggesting an investment in any company or investment opportunity. You the investor are making decisions for yourself.

We may have an inherent conflict of interest by sending the newsletter at the same time we may own stock in the same company or even have been paid compensation at the time of the promotion. www.otpicks.com reserve the right to sell shares at anytime, even during the time period in which we are profiling a company. Under no circumstances shall any member of www.otpicks.com be held liable for any loss incurred by any individual or individuals as a result of any individual or individuals decision to invest in any company profiled by www.otpicks.com .Viewing this web site and viewing picks on this web site or Newsletter sent to subscribers shall not create under any circumstances an offer to buy or sell stock in any company profiled. Nor shall it create any principal-agent relationship between viewer and www.otpicks.com Short term investing involves significant risk, and you can lose some or all of your investing capital. Please contact a qualified financial planner before investing in any stocks, including those profiled by [16] www.otpicks.com .

www.otpicks.com may trade in fast moving, highly volatile markets, and any viewer of www.otpicks.com web site should observe the trading behavior of any profiled company prior to purchasing. www.otpicks.com selections are primarily intended for short term momentum trading and carry a high degree of risk.

www.otpicks.com also profiles long term trading and those profiles also carry a great deal of risk.

Past performance of www.otpicks.com is not indicative of future results. In making selections, www.otpicks.com may make use of any public information including but not limited to company issued press releases, SEC filings, profiles from Hoovers or Marketguide, brokerage reports, newspapers, magazines, journals, electronic databases on the web, electronic message board postings on the web and other research sites. www.otpicks.com attempts to verify the accuracy of the information contained in said resources, but does not represent or warrant the accuracy contained in these resources. Investors should, at no time, rely solely on the information contained in www.otpicks.com picks and are urged to research profiled companies on their own, and make their own investment decision. Factual statements on this web site or the Newsletter sent to subscribers are made as of the date stated and are subject to change without notice. The Securities and Exchange Commission has compiled an extensive amount of information concerning online investing, including the inherent risks involved. We encourage our readers to visit the SECs web site to acquire this important information.

Safe Harbor Disclosure:

The www.otpicks.com web site contains or incorporates by reference forward-looking statements, including certain information with respect to plans and strategies of the featured company. As such, any statements contained herein or incorporated herein by reference that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the forgoing, the words believe(s), anticipate(s), plan(s), expect(s), project(s) will make told and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause actual events or actual results of the Companies profiled herein to differ materially from these indicated by such forward-looking statements. Certain statements contained herein constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Such statements include, without limitation, statements regarding business and financing, business trends, future operating revenues and expenses.

Although the Company believes that the statements are reasonable, it can give no assurances that such expectations will prove to be correct. Investors are cautioned that any forward looking statements made by the Company, or contained in any and/or all profile/research reports, contain no guarantee of future performance, and that the actual result may differ materially from those set forth in the forward-looking statements. Difference in results can be caused by various factors including, but not limited to, the Companys ability to be able to successfully complete planned funding agreements, to successfully market its products in competitive industries or to effectively implement its business plan or strategies. In order to be in full compliance with the U.S. Securities Act of 1933, Section 17(b), www.otpicks.com discloses all compensation it receives at the bottom of its newsletter or profile company pages.

Information presented within this report contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact and may be forward looking statements.

Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as expects, will, anticipates, estimates, believes, may, or by statements indicating certain actions may, could, or might occur. We encourage our readers to invest carefully and review all forms of investments and read the investor information. More information on the Company may be found at [17]http://www.sec.gov and/or the National Association of Securities Dealers (NASD) at: [18]http://www.nasd.com. Readers can review all public filings by companies at the SECs EDGAR page. The NASD has published information on how to invest carefully at its web site.

The content in these newsletters and on the www.otpicks.com web site are provided for informational purposes only. Use of www.otpicks.com Web sites, logos, themes, or other items contained within this report are prohibited without the express written consent of [19] www.otpicks.com .

Links to Other Websites. The Site may contain links to other Internet websites or resources. We neither control nor endorse such other websites, nor have we reviewed or approved any content that appears on such other websites. You acknowledge and agree that we shall not be held responsible for the legality, accuracy, or inappropriate nature of any content, advertising, products, services, or information located on or through any other websites, nor for any loss or damages caused or alleged to have been caused by the use of or reliance on any such content.

Any redistribution of information from this web site or our newsletter e-mails without the written consent of www.otpicks.com is strictly prohibited.

ONTIMEPICKS (OTP) has a no tolerance spam policy, we will not sell or redistribute your email to any 3rd party. If applicable, please

Related posts:

1. ** VIP Early Alert- CWNM is our Extraordinary New Pharmaceutical Epic Pick! **
2. CWNM Latest News Could Change The Pharma Industry For Good – Will You Profit From It?
3. * CWNM * is our -Red Hot Pharmaceutical Play- for Thursday! Must Read Info Inside…
4. * CWNM * This Red Hot Pharmaceutical Alert Could See New Highs Very Shortly
5. ** Could CWNM become the Next VIRAL Pharmaceutical Play? **